Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 Shares

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mark Schoenberg also recently made the following trade(s):

• On Monday, July 28th, Mark Schoenberg sold 5,149 shares of Urogen Pharma stock. The shares were sold at an average price of $19.14, for a total transaction of $98,551.86.
• On Monday, June 9th, Mark Schoenberg sold 5,162 shares of Urogen Pharma stock. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94.

Urogen Pharma Trading Up 4.7%

Urogen Pharma stock opened at $20.11 on Thursday. The firm has a 50 day moving average of $14.91 and a 200 day moving average of $11.52. The firm has a market capitalization of $930.29 million, a price-to-earnings ratio of -6.06 and a beta of 1.12. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $21.01.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. The firm had revenue of $24.22 million during the quarter, compared to analysts’ expectations of $23.06 million. On average, analysts predict that Urogen Pharma will post -3.12 EPS for the current year.

Institutional Investors Weigh In On Urogen Pharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP grew its holdings in Urogen Pharma by 79.7% during the 2nd quarter. Marshall Wace LLP now owns 20,660 shares of the company’s stock valued at $283,000 after buying an additional 9,160 shares in the last quarter. Walleye Capital LLC purchased a new stake in Urogen Pharma during the 2nd quarter valued at approximately $4,742,000. Panagora Asset Management Inc. grew its holdings in Urogen Pharma by 181.9% during the 2nd quarter. Panagora Asset Management Inc. now owns 261,785 shares of the company’s stock valued at $3,586,000 after buying an additional 168,908 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Urogen Pharma by 5.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock valued at $5,348,000 after buying an additional 19,405 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in Urogen Pharma during the 2nd quarter valued at approximately $265,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. The Goldman Sachs Group set a $16.00 target price on shares of Urogen Pharma and gave the company a “neutral” rating in a research note on Friday, June 13th. Scotiabank reiterated an “outperform” rating on shares of Urogen Pharma in a research note on Friday, June 13th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Urogen Pharma in a research note on Tuesday, August 5th. Guggenheim reiterated a “buy” rating and issued a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Finally, Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Friday, June 13th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.43.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.